Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 2/20 | 0.42 |
| ▸ | NOS3 | P29474 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | CDA | P32320 | 2/20 | 0.36 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.34 |
| ▸ | HTR2C | P28335 | 2/20 | 0.33 |
| ▸ | HTR2B | P41595 | 2/20 | 0.33 |
| ▸ | F10 | P00742 | 1/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5951577 | 0.94 | CDA (0.38) | NOS1NOS3ALDH1A1MEN1KMT2A | |
| SCHEMBL19271812 | 0.87 | CDA (0.42) | NOS1NOS3KDM4EALDH1A1CDA | |
| SCHEMBL17138754 | 0.87 | CDA (0.42) | NOS1NOS3KDM4EALDH1A1MEN1 | |
| SCHEMBL16400703 | 0.86 | — | — | |
| SCHEMBL11215508 | 0.85 | CDA (0.44) | NOS1NOS3KDM4EALDH1A1GAA | |
| SCHEMBL17138583 | 0.84 | KDM4E (0.39) | NOS1NOS3KDM4EALDH1A1KMT2A | |
| SCHEMBL9202125 | 0.84 | KDM4E (0.39) | KDM4EALDH1A1GAAKMT2ANPY5R | |
| SCHEMBL5827421 | 0.84 | CDA (0.44) | NOS1NOS3KDM4EALDH1A1CDA | |
| SCHEMBL25307809 | 0.83 | CDA (0.46) | NOS1NOS3KDM4EALDH1A1GAA | |
| SCHEMBL10982543 | 0.83 | CDA (0.46) | NOS1NOS3KDM4EALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050239804-A1 | Method for improved chemical synthesis of guanidinium alkaloids | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2005-10-27 | — | — | US | disclosed |
| EP-1204666-A1 | HEXAHYDROPYRROLO[1,2-C]PYRIMIDINES AS ANTIVIRAL, ANTIFUNGAL AND/OR ANTITUMOR AGENTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2002-05-15 | — | — | EP | disclosed |
| WO-2001000626-A1 | HEXAHYDROPYRROLO[1,2-C]PYRIMIDINES AS ANTIVIRAL, ANTIFUNGAL AND/OR ANTITUMOR AGENTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2001-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239804-A1 | Method for improved chemical synthesis of guanidinium alkaloids | PAICS, TYMS, IMPDH1 | NOS1 497/4885NOS3 1199/4885KDM4E 2907/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.